中国实用内科杂志2025，Vol.45Issue(6)：449-453,5.DOI:10.19538/j.nk2025060101
早期肺癌新型分子诊断的意义及评价
Significance and evaluation of novel molecular diagnosis methods for early lung cancer
摘要
Abstract
The early diagnosis of lung cancer is crucial to increasing the survival rates of patients,and molecular diagnosis methods represents a new direction.Research on molecular biomarkers for early-stage lung cancer diagnosis is showing a multi-dimensional development trend.The model constructed by traditional protein biomarkers combined with imaging features can enhance risk prediction efficacy,but its sensitivity for sub-centimeter nodules remains insufficient.Novel biomarkers such as ProGRP and circulation tumor DNA(ctDNA)methylation have significantly improved detection performance through technological innovations,yet many biomarkers are still limited by low sensitivity.Current challenges focus on the limitations of biomarker sensitivity,the lack of survival benefit evidence,and unclear clinical translation pathways.Future advancements call for multi-dimensional integration and liquid biopsy innovations to drive breakthroughs in early diagnosis,ultimately achieving a shift of diagnosis and treatment paradigm from"treating advanced cancer"to"preventing early cancer".关键词
早期肺癌/分子诊断/液体活检Key words
early-stage lung cancer/molecular diagnosis/liquid biopsy分类
医药卫生引用本文复制引用
王子奇,张晓菊..早期肺癌新型分子诊断的意义及评价[J].中国实用内科杂志,2025,45(6):449-453,5.基金项目
国家自然科学基金(82370002,8240002) （82370002,8240002）
河南省科技攻关项目(242102311037) （242102311037）
